Reproducibility of an objective four-choice canine vision testing technique that assesses vision at differing light intensities

Veterinary Ophthalmology

Volumn 16, Issue 5, 2013, Pages 324-328

  Annear, Matthew J ^a   Gornik, Kara R ^b   Venturi, Francesca L ^a   Hauptman, Joe G ^b   Bartoe, Joshua T ^b   Petersen Jones, Simon M ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Canine; Dystrophy; Retina; RPE65; Testing; Vision

Indexed keywords

CIS TRANS ISOMERASE; RETINOID ISOMEROHYDROLASE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANINE; DOG; DOG DISEASE; DYSTROPHY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIGHT; MALE; METABOLISM; RETINA; RETINA DISEASE; RPE65; TESTING; VISION; VISION TEST;

CANINE; DYSTROPHY; RETINA; RPE65; TESTING; VISION;

ANIMALS; CIS-TRANS-ISOMERASES; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIGHT; MALE; RETINAL DISEASES; VISION TESTS;

EID: 84883274815     PISSN: 14635216     EISSN: 14635224     Source Type: Journal    
DOI: 10.1111/j.1463-5224.2012.01076.x     Document Type: Article

References (20)

1. Acland GM, Aguirre GD, Bennett J et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Molecular Therapy: The Journal of the American Society of Gene Therapy 2005; 12: 1072-1082. Epub 2005/10/18.
2. Gearhart PM, Gearhart C, Thompson DA et al. Improvement of visual performance with intravitreal administration of 9-cis-retinal in Rpe65-mutant dogs. Archives of Ophthalmology 2010; 128: 1442-1448. Epub 2010/09/15.
3. Komaromy AM, Alexander JJ, Rowlan JS et al. Gene therapy rescues cone function in congenital achromatopsia. Human Molecular Genetics 2010; 19: 2581-2593. Epub 2010/04/10.
4. Beltran WA, Cideciyan AV, Lewin AS et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: 2132-2137. Epub 2012/02/07.
5. Acland GM, Aguirre GD, Ray J et al. Gene therapy restores vision in a canine model of childhood blindness. Nature Genetics 2001; 28: 92-95. Epub 2001/04/28.
6. Narfstrom K, Katz ML, Ford M et al. In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement. The Journal of Heredity 2003; 94: 31-37. Epub 2003/04/15.
7. Garcia MM, Ying GS, Cocores CA et al. Evaluation of a behavioral method for objective vision testing and identification of achromatopsia in dogs. American Journal of Veterinary Research 2010; 71: 97-102. Epub 2010/01/02.
8. Beltran WA. The use of canine models of inherited retinal degeneration to test novel therapeutic approaches. Veterinary Ophthalmology 2009; 12: 192-204. Epub 2009/04/28.
9. Gearhart PM, Gearhart CC, Petersen-Jones SM. A novel method for objective vision testing in canine models of inherited retinal disease. Investigative Ophthalmology & Visual Science 2008; 49: 3568-3576. Epub 2008/07/29.
10. Annear MJ, Bartoe JT, Barker SE et al. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Therapy 2011; 18: 53-61. Epub 2010/08/13.
11. Narfstrom K, Wrigstad A, Nilsson SE. The Briard dog: a new animal model of congenital stationary night blindness. The British Journal of Ophthalmology 1989; 73: 750-756. Epub 1989/09/01.
12. Wrigstad A, Narfstrom K, Nilsson SE. Slowly progressive changes of the retina and retinal pigment epithelium in Briard dogs with hereditary retinal dystrophy. A morphological study. Documenta Ophthalmologica. Advances in Ophthalmology 1994; 87: 337-354. Epub 1994/01/01.
13. Wrigstad A, Nilsson SE, Narfstrom K. Ultrastructural changes of the retina and the retinal pigment epithelium in Briard dogs with hereditary congenital night blindness and partial day blindness. Experimental Eye Research 1992; 55: 805-818. Epub 1992/12/01.
14. Aguirre GD, Baldwin V, Pearce-Kelling S et al. Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect. Molecular Vision 1998; 4: 23. Epub 1998/11/11.
15. Veske A, Nilsson SE, Narfstrom K et al. Retinal dystrophy of Swedish briard/briard-beagle dogs is due to a 4-bp deletion in RPE65. Genomics 1999; 57: 57-61. Epub 1999/04/07.
16. Bainbridge JW, Smith AJ, Barker SS et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. The New England Journal of Medicine 2008; 358: 2231-2239. Epub 2008/04/29.
17. Hauswirth WW, Aleman TS, Kaushal S et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Human Gene Therapy 2008; 19: 979-990. Epub 2008/09/09.
18. Maguire AM, Simonelli F, Pierce EA et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. The New England Journal of Medicine 2008; 358: 2240-2248. Epub 2008/04/29.
19. Simonelli F, Maguire AM, Testa F et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5years after vector administration. Molecular Therapy: The Journal of the American Society of Gene Therapy 2010; 18: 643-650. Epub 2009/12/03.
20. Cideciyan AV, Hauswirth WW, Aleman TS et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1year. Human Gene Therapy 2009; 20: 999-1004. Epub 2009/07/09.